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Mitotic centromere-associated kinesin (MCAK) is a microtubule depolymerase that is essential for proper kinetochore–microtubule
attachment during spindle formation. Overexpression of MCAK has been correlated with aggressive forms of carcinoma, resulting in
poor prognosis of colorectal cancer. The purpose of this study was to quantify MCAK expression in malignant and benign colorectal
tissues and to determine if MCAK expression levels correlate with clinicopathologic factors and prognosis in colorectal cancer
patients. Paired colorectal tissue samples from tumours and the corresponding normal tissues were obtained from 120 patients with
colorectal cancer who underwent surgical resection. The real-time reverse transcriptase-PCR and immunohistochemistry were used
to analyse mRNA and protein expression status with respect to various clinicopathological factors. MCAK expression was higher in
colorectal cancer tissue (Po0.01) than in corresponding normal tissue, and this elevated expression level was markedly associated
with factors such as lymph node metastasis (P¼0.0023), venous invasion (P¼0.019), peritoneal dissemination (P¼0.021) and
Dukes’ classification (P¼0.0023). Patients with high MCAK mRNA expression also showed a far poorer survival rate than those with
low MCAK mRNA expression (Po0.01). Elevated MCAK expression was an independent predictor of overall survival and lymph
node metastasis. These data suggest that MCAK expression may serve as a good marker of prognosis and lymph node metastasis in
colorectal cancer.
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Colorectal cancer is one of the most prevalent cancers in the world,
accounting for nearly 10% of all cancer cases (Parkin et al, 2001).
In Japan, the incidence of colorectal cancer has significantly
increased during the past 50 years, in concert with changes in
eating habits, other lifestyle parameters and longevity (Kono,
1996). Colorectal cancer is now the second most important cause
of death from neoplastic disease in Japan (Tsukuma et al, 2004).
Identification of the genes responsible for the development and
progression of colorectal cancer is critical if improvements are to
be made in the diagnosis and treatment of the disease.
Chromosomal instability, a recognisable feature of human
cancers, is caused by continuous chromosomal missegregation
during mitosis (Tomonaga et al, 2005). A physical connection (i.e.,
a kinetochore) between the spindle microtubules (MTs) and
centromeric DNA is essential for appropriate chromosomal
segregation (Tomonaga et al, 2005). During spindle formation,
mitotic centromere-associated kinesin (MCAK), a microtubule
depolymerase, ensures proper kinetochore–MT attachment
(Holmfeldt et al, 2005). An attachment failure leads to missegrega-
tion of individual chromosomes.
MCAK, located at chromosome 1p34.1, is a member of the
kinesin-13 subfamily that shares homology with other members of
the kinesin superfamily (Wordeman and Mitchison, 1995; Vale and
Fletterick, 1997; Lawrence et al, 2004) that play important roles in
intracellular transport and cell division (Wittmann et al, 2001).
Mitotic centromere-associated kinesin is present throughout the
cell, but is especially concentrated at the centromeres, kineto-
chores and spindle poles (Gorbsky, 2004). Although other kinesins
act to transport cargo, MCAK and other kinesin-13 members
catalyse MT disassembly, an important factor in normal chromo-
some movement (Helenius et al, 2006). Mitotic centromere-
associated kinesin destabilises MTs from either end, and this
activity and localisation are under the regulation of mitotic kinases
(Wordeman et al, 2007). Overexpression of wild-type MCAK
induces destabilisation of MTs in both mitotic and interphase cells
(Kline-Smith and Walczak, 2002).
We recently reported that elevated MCAK expression is
associated with lymphatic invasion, lymph node metastasis
and poor prognosis in gastric cancer (Nakamura et al, 2007).
Although MCAK mRNA is also highly expressed in colorectal
cancer tissues (Mori et al, 1993a), no clinicopathologic analysis
of MCAK expression in human colorectal cancer has been
reported. In this study, we explored MCAK gene expression
in human colorectal cancer and evaluated possible associations
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prognosis.
MATERIALS AND METHODS
Cell lines and clinical tissue samples
Cell lines derived from human colorectal cancer (DLD1, COLO201,
COLO205, COLO320DM, HT29, HCT15, WiDr, SW480, LS174T,
CCK81, RCM1 and CaR1) were obtained from the Cell Resource
Centre for Biomedical Research Institute of Development, Aging
and Cancer (Tohoku University, Sendai, Japan) and maintained in
RPMI-1640 containing 10% fetal bovine serum and antibiotics at
371C in a 5% humidified CO2 atmosphere.
One hundred and twenty patients (70 men, 50 women) with
colorectal cancer who underwent surgery at the Medical Institute of
Bioregulation at Kyushu University from 1994 to 1999 were included
in this study. Primary colorectal cancer specimens and adjacent
normal colorectal mucosa were obtained from patients after
informed consent had been obtained in accordance with the
institutional guidelines of the hospital. Immediately after resection,
the necrotic and ulcerated portions of the tumours were removed
and normal colonic mucosa was dissociated from muscle and
connective tissue. All specimens were immediately frozen in liquid
nitrogen and kept at  801C until RNA extractions were performed.
Every patient was definitively identified as having colorectal cancer
based on the clinicopathologic findings. None of the patients
received chemotherapy or radiotherapy prior to surgery. Clinico-
pathological factors were assessed according to the criteria of the
Japanese Classification of Colorectal Carcinoma (Japanese Society for
Cancer Colon and Rectum, 1998). All patients were closely followed
after surgery at regular 1-month intervals for 2–72 months, with a
mean follow-up period of 38.4 months. This study was conducted
under the supervision of the ethical board of Kyushu University.
RNA preparation and reverse transcription
Total RNA was isolated using a modified acid guanidinium–
phenol–chloroform procedure with DNase (Mimori et al, 1997).
cDNA was synthesised from 2.5mg of total RNA as described
previously (Mori et al, 1993b).
MCAK gene amplification
A 237-bp MCAK fragment was amplified with the following
primers: 50-GATGGAAGCCTGCTCTAACG-30 (forward) and 50-
GAGCAGATTCCGCTTTGTTC-30 (reverse). The forward primer is
located in exon 8 and the reverse primer in exon 9. The
amplification parameters were 1min at 951C, 1min at 621C and
1min at 721C for 28 cycles. An 8-ml aliquot of each reaction
mixture was size-fractionated in a 2% agarose gel and visualised by
ethidium bromide staining. To ensure that the RNA was not
degraded, a PCR assay with primers specific for the glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) gene was performed
for 1min at 951C, 1min at 561C and 1min at 721C for 28 cycles.
The GAPDH primers 50-TTGGTATCGTGGAAGGACTCA-30 (for-
ward) and 50-TGTCATCATATTTGGCAGGTT-30 (reverse) pro-
duced a 270-bp amplicon (Ogawa et al, 2004). cDNA from the
Human Universal Reference Total RNAs (Clontech, Palo Alto, CA,
USA) was studied concurrently as a source of positive controls.
Confirmation of reverse transcriptase-PCR (RT-PCR) products
was performed by direct sequencing analysis.
Real-time quantitative reverse transcriptase-PCR
Real-time monitoring of the PCRs was performed using the
LightCycler FastStart DNA Master SYBR Green I Kit (Roche
Diagnostics, Tokyo, Japan). The amplification protocol consisted
of 35 cycles of denaturation at 951C for 10s, annealing at 641C for
10s and elongation at 721C for 10s. The products were then
subjected to a temperature gradient from 681Ct o9 5 1C at 0.11Cs
 1
with continuous fluorescence monitoring to produce a melting
curve of the products. After proportional background adjustment,
the fit point method was used to determine the cycle in which the
log-linear signal was distinguished from the background, and that
cycle number was used as a crossing-point value. The standard
curve was produced by measuring the crossing point of each
standard value (twofold serially diluted cDNAs from the Human
Universal Reference Total RNAs) and plotting them against the
logarithmic value of the concentration. The concentration of each
sample was then calculated by setting their crossing points to the
standard curve. The expression levels were normalised against
GAPDH mRNA expression (Ogawa et al, 2004).
Immunohistochemistry
Colorectal cancer surgical specimens from formalin-fixed, paraffin-
embedded tissues were used for MCAK immunohistochemistry.
After deparaffinisation and blocking, the antigen–antibody reac-
tion was incubated overnight at 41C. ENVISION reagents
(ENVISIONþDual Link/HRP; Dako Cytomation, Glostrup,
Denmark) were applied to detect the signal from the antigen–
antibody reaction. All sections were counterstained with haema-
toxylin. The primary anti-MCAK goat polyclonal antibody
(ab5966; Abcam, Cambridge, UK) was used at a dilution of 1:500.
Statistical analysis
For continuous variables, the data were expressed as the
mean±s.d. The relationship between MCAK mRNA expression
and the clinicopathological factors was analysed by the w
2 test and
Student’s t-test. Kaplan–Meier survival curves were plotted and
compared with the generalised log rank test. Prognostic factors
were evaluated by univariate and multivariate analyses (Cox
proportional hazard regression model). A logistic regression
model was used to identify the independent predictors of lymph
node metastasis. All tests were analysed by JMP software (SAS
Institute, Cary, NC, USA), and the findings were considered
statistically significant at Po0.05.
RESULTS
MCAK mRNA expression in colorectal cancer cell lines and
clinical tissue specimens
Figure 1A shows MCAK gene expression status in human colorectal
cancer cell lines from RT-PCR analysis. Twelve of the 13 cell lines
(92%) expressed the MCAK gene; COLO201 was the exception. We
also performed RT-PCR analysis of MCAK in colorectal cancers and
paired normal samples obtained from seven patients. In all seven
cases, MCAK expression was higher in the cancer tissues than in
paired normal tissue (Figure 1B). Quantitative real-time RT-PCR was
performed using the Human Total RNA Master Panel (Clontech) to
characterise MCAK mRNA expression. MCAK expression was
extremely high in the testis. Lower expression was found in the
digestive organs (colon and intestines), possibly a reflection of basic
mitosis of the mucosa (data not shown). Moreover, quantitative real-
time RT-PCR on 120 paired clinical samples showed that 91 of 120
cases (75.8%) exhibited higher levels of MCAK mRNA in tumours
than in paired normal samples. The mean expression value of MCAK
mRNA in tumour samples, 0.53±0.037 (mean±s.d., normalised by
GAPDH gene expression), was significantly higher than the value,
0.32±0.037, for the corresponding normal samples (Po0.01;
Student’s t-test).
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A positive immunohistochemical staining pattern for MCAK in
tissue from a colorectal cancer patient is shown in Figure 2A and B.
Mitotic centromere-associated kinesin protein staining was
observed in the cytoplasm of cancer cells, but not in the stromal
cells nor in normal epithelium. Mitotic centromere-associated
kinesin protein expression was examined in the tumours and
corresponding normal tissues from 15 representative colorectal
cancer cases. Of these 15 cases, seven exhibited a higher level of
MCAK mRNA expression in tumour tissues, whereas the remain-
ing eight cases showed a lower level of MCAK mRNA in cancerous
tissue. All sections were independently examined for protein
expression and scored as positive or negative when 410%
(positive) or o10% (negative) of carcinoma cells were stained in
an examined area of a specimen. As a result, nine of the
representative cases showed a positive reaction for MCAK, whereas
six cases were negative. The data were similar to those obtained
from MCAK mRNA expression analysis. The six negative tumours
(Figure 2C and D) also showed lower mRNA expression levels,
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Figure 1 MCAK mRNA expression in colorectal cancer cell lines and clinical tissue specimens. (A) Reverse transcriptase-PCR analysis of MCAK expression
in human colorectal cancer cell lines. Twelve of the 13 cell lines (92%) expressed the MCAK gene, whereas COLO201 did not. (B) Reverse transcriptase-
PCR analysis of MCAK expression in clinical samples of colorectal cancer. MCAK expression was determined in the colorectal tumours (T) and paired normal
(N) samples obtained from seven patients. In all seven cases, MCAK expression was higher in the tumours than in the normal tissues. GAPDH was used as a
loading control. m¼marker; NC¼negative control; PC¼positive control.
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Figure 2 Immunohistochemical staining for MCAK in tumour specimens. (A and B) A representative positive stain for MCAK in tissue from a colorectal
cancer patient. Positive staining is observed in the cytoplasm of cancer cells, but not in the stromal cells nor in normal epithelium. Solid line arrows indicate
cancer cells that are positive for MCAK expression. (C and D) A representative negative stain for MCAK in a colorectal cancer specimen. Dotted line arrows
indicate cancer cells that are negative for MCAK expression. Mitotic centromere-associated kinesin protein expression was evaluated in tumours and
corresponding normal tissues from 15 representative colorectal cancer cases. The six tumours that were negative for protein expression (C and D) also
exhibited lower mRNA expression levels, whereas seven of nine tumours with a positive immunohistochemical expression (A and B) displayed elevated
mRNA expression levels. The expression of MCAK mRNA was thereby associated with protein expression. Each solid square in (A) and (C) was magnified
 100 and shown in (B) and (D), respectively (original magnification; (A) and (C),  40; (B) and (D),  100).
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higher mRNA expression levels. These data suggest that MCAK
mRNA expression is associated with protein expression.
MCAK mRNA expression and clinicopathological
characteristics
The experimental samples were divided into two expression
groups. Patients who had less than the median expression ratio
of tumour to normal tissue (T/N) were assigned to the low-
expression group (n¼81); the others were assigned to the high-
expression group (n¼39). Clinicopathological factors related to
MCAK expression status are listed in Table 1. The incidence of
three of these factors was positively correlated with increased
expression (i.e., the high-expression group): (1) lymph node
metastasis was significantly higher (P¼0.0023) in the high-
expression group (25 of 39, 64.1%) than in the low-expression
group (28 of 81, 34.6%); (2) the incidence of venous invasion was
significantly higher (P¼0.019) in the high-expression group (13 of
39, 33.3%) than in the low-expression group (12 of 81, 14.8%); and
(3) the incidence of peritoneal dissemination was significantly
higher in the high-expression group (4 of 39, 10.3%) than in the
low-expression group (1 of 81, 1.23%). Moreover, the incidence of
advanced stage cancer (according to Dukes’ classification) was
significantly higher (P¼0.0023) in the high-expression group (26
of 39, 66.7%) than in the low-expression group (30 of 81, 37.0%).
The other clinicopathological factors were not correlated with
MCAK overexpression.
Relationship between MCAK expression and prognosis
The 5-year survival rate was significantly lower in patients with
elevated MCAK expression (Po0.01; Figure 3). Table 2 provides
the univariate and multivariate analyses of factors related to
patient prognosis. Univariate analysis showed that the following
factors were significantly related to postoperative survival: tumour
size (P¼0.009), serosal invasion (Po0.0001), lymph node
metastasis (Po0.0001), lymphatic invasion (Po0.0001) and MCAK
mRNA expression (P¼0.019). Multivariate regression analysis
indicated that inclusion in the MCAK mRNA high-expression
group (relative risk (RR), 1.42; 95% confidence interval (CI), 1.01–
2.00; Po0.05) was an independent predictor of overall survival, as
were serosal invasion (RR, 2.16; 95% CI, 1.52–3.12; Po0.0001) and
lymph node metastasis (RR, 1.82; 95% CI, 1.26–2.76; P¼0.0012).
Multivariate analysis for lymph node metastasis
Univariate and multivariate logistic regression analyses were
performed on lymph node metastasis (Table 3). Univariate analysis
revealed a significant relationship between lymph node metastasis
and the following factors: histological grade (P¼0.04), tumour size
(P¼0.01), depth of invasion (P¼0.02), lymphatic invasion
(Po0.0001), venous invasion (P¼0.003) and MCAK mRNA
expression (P¼0.003). Multivariate regression analysis indicated
that inclusion in the MCAK mRNA high-expression group (RR,
4.02; 95% CI, 1.53–11.3; Po0.006) was an independent predictor
of lymph node metastasis in addition to lymphatic invasion (RR,
7.67; 95% CI, 3.01–21.1; Po0.0001).
DISCUSSION
In this study, we demonstrated that MCAK is expressed at higher
levels in colorectal cancer cells than in the corresponding normal
tissues. Mitotic centromere-associated kinesin overexpression
causes a moderate increase in the frequency of multipolar spindles
(Holmfeldt et al, 2004) and monopolar spindles (Kline-Smith and
Walczak, 2002), which can contribute to the gain or loss of
chromosomes in daughter cells. We reported that overexpression
of MCAK leads to the increased migratory and proliferative ability
of gastric cancer cells (Nakamura et al, 2007). Microtubules, key
components of the cytoskeleton, play essential roles in mitosis, cell
migration, and cell signalling and trafficking (Honore et al, 2005).
Mitotic centromere-associated kinesin is present throughout the
cell, and overexpression of MCAK may accelerate MT turnover,
resulting in the gain of cancer cell motility. This result may
partially explain the finding that gastric cancer patients with
tumours that express high levels of MCAK had higher rates of
lymphatic invasion and metastasis, and a poorer prognosis. Along
the same line, downregulation of MCAK in a breast cancer study
resulted in tumour growth suppression (Shimo et al, 2008). These
findings suggest that overexpression of MCAK enhances the
malignancy of cancer cells.
Clinicopathological analysis revealed that tumours with high
MCAK expression were associated with lymph node metastasis,
venous invasion, peritoneal dissemination and advanced Dukes’
Table 1 Clinicopathological factors and MCAK mRNA expression in 120
colorectal cancers
Factors
High expression
(%) (n¼39)
Low expression
(%) (n¼81) P-value
Age (mean±s.d.) 65.3±12.3 66.9±11.3 0.49
Gender
Male 22 (56.4) 48 (59.3) 0.76
Female 17 (43.6) 33 (40.7)
Histological grade
Well 15 (38.5) 29 (35.8) 0.78
Others (moderately,
poorly and mucinous)
24 (61.5) 52 (64.2)
Tumour size
o30mm (small) 8 (20.5) 17 (21.0) 0.95
X30mm (large) 31 (79.5) 64 (79.0)
Serosal invasion
Absent 26 (66.7) 59 (72.8) 0.49
Present 13 (33.3) 22 (27.2)
Lymph node metastasis
Absent 14 (35.9) 53 (65.4) 0.0023*
Present 25 (64.1) 28 (34.6)
Lymphatic invasion
Absent 22 (56.4) 53 (65.4) 0.34
Present 17 (43.6) 28 (34.6)
Venous invasion
Absent 26 (66.7) 69 (85.2) 0.019*
Present 13 (33.3) 12 (14.8)
Liver metastasis
Absent 33 (84.6) 73 (90.1) 0.38
Present 6 (15.4) 8 (9.9)
Peritoneal dissemination
Absent 35 (89.7) 80 (98.8) 0.021*
Present 4 (10.3) 1 (1.2)
Dukes’ classification
A and B 13 (33.3) 51 (63.0) 0.0023*
C and D 26 (66.7) 30 (37.0)
s.d.¼standard deviation. *Po0.05.
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expression in cancer tissues was significantly higher than
expression in nonmalignant tissue, and elevated MCAK expression
was significantly associated with lymphatic invasion and lymph
node metastasis (Nakamura et al, 2007). These results suggest that
MCAK plays a pivotal role in the progression of colorectal cancer
and gastric cancer. Moreover, in both studies, patients with high
MCAK expression had a poorer survival rate than those with low
MCAK expression, and high MCAK expression was an independent
prognostic factor for overall survival in the Cox proportional
hazard regression model. To our knowledge, this is the first report
on correlations between MCAK gene expression and clinicopatho-
logical factors in colorectal cancer. In the majority of colorectal
cancer reports, gene expression is secondary to TNM or Dukes’
classification as a prognostic marker. Because its expression is an
independent prognostic factor, the expression profile of MCAK
may contribute to the creation of a new clinical classification
system.
Another aspect of this study is the relationship between MCAK
expression and lymphatic extension. Interestingly, multivariate
analysis for lymph node metastasis revealed that MCAK mRNA
expression is a good predictor of lymph node metastasis. Lymph
node metastases are the most important predictors of survival in
non-stage IV colorectal cancer (Schumacher et al, 2007). Today,
we have several options for curative treatment of early colorectal
cancer, such as endoscopic mucosal resection (EMR), endoscopic
submucosal dissection (ESD) and laparoscopic-assisted colectomy
with regional lymphadenectomy. In limited cases, patients
are eligible for such less invasive surgery. Patients suitable for
those endoscopic treatments are selected by the preoperative
diagnosis of lymph node metastasis, such as macroscopic
type, tumour size, presence of an ulcer and histology of biopsy
specimens. However, some patients are misdiagnosed and actually
do have lymph node metastasis before the operation. By
incorporating the genetic diagnosis of MCAK gene expression,
preoperative selection for patients without lymph node metastasis
may be possible. Furthermore, it has been reported that with
SELEX, MCAK was detected in the peripheral blood of a colon
cancer patient (Scanlan et al, 2002), suggesting that the blood level
of MCAK can be used for the prediction of lymph node metastasis.
The analysis of MCAK using biopsied specimens and blood
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Figure 3 Kaplan–Meier survival curves of patients with colorectal cancer
based on MCAK mRNA expression status. Patients in the high-expression
group (bold line) showed significantly poorer prognosis than those in the
low-expression group (dotted line; Po0.01, log rank test).
Table 2 Univariate and multivariate analysis for overall survival (Cox proportional hazards regression model)
Univariate analysis Multivariate analysis
Factors RR 95% CI P-value RR 95% CI P-value
Age (o60/60 p) 0.82 0.58–1.20 0.29 — — —
Gender (male/female) 0.96 0.68–1.33 0.81 — — —
Histological grade (well/moderately, poorly and mucinous) 1.21 0.86–1.76 0.29 — — —
Tumour size (o30mm/X30mm) 1.93 1.16–3.94 0.009 1.29 0.74–2.70 0.4
Serosal invasion (absent/present) 2.40 1.72–3.38 o0.0001 2.16 1.52–3.12 o0.0001
Lymph node metastasis (absent/present) 2.25 1.58–3.38 o0.0001 1.82 1.26–2.76 0.0012
Lymphatic invasion (absent/present) 2.30 1.64–3.31 o0.0001 — — —
Venous invasion (absent/present) 1.43 0.99–2.00 0.055 — — —
MCAK mRNA expression (T/No3/T/N43) 1.49 1.07–2.07 0.019 1.42 1.01–2.00 0.048
CI¼confidence interval; RR¼relative risk.
Table 3 Univariate and multivariate analysis for lymph node metastasis (logistic regression model)
Univariate analysis Multivariate analysis
Factors RR 95% CI P-value RR 95% CI P-value
Age (o60/60 p) 0.44 0.18–1.108 0.08 — — —
Gender (male/female) 0.86 0.41–1.79 0.69 — — —
Histological grade (well/moderately, poorly and mucinous) 2.26 1.05–5.02 0.04 2.21 0.84–6.09 0.11
Tumour size (o30mm/X30mm) 4.08 1.51–13.1 0.01 2.52 0.72–10.1 0.17
Tumour stage (T1/T2–T4) 4.40 1.34–19.9 0.02 1.25 0.26–7.09 0.79
Lymphatic invasion (absent/present) 9.11 3.98–22.3 o0.0001 7.67 3.01–21.1 o0.0001
Venous invasion (absent/present) 4.41 1.56–8.25 0.003 2.01 0.66–6.48 0.23
MCAK mRNA expression (T/No3/T/N43) 3.38 1.54–7.67 0.003 4.02 1.53–11.3 0.006
CI¼confidence interval; RR¼relative risk.
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translate to minimally invasive treatments for early colorectal
cancer.
In conclusion, the expression of MCAK in colorectal cancer was
elevated respective to levels in normal colorectal tissue, and this
overexpression was associated with lymph node metastasis, venous
invasion, peritoneal dissemination and poor prognosis. In
particular, MCAK mRNA overexpression was associated with
prognosis and lymph node metastasis in a multivariate analysis.
Therefore, MCAK could be a useful predictive marker of lymph
node metastasis, which might permit minimally invasive and
curative treatments combining EMR and ESD for early colorectal
cancer.
ACKNOWLEDGEMENTS
We thank Dr Y Nakamura, Ms T Shimooka, Ms K Ogata, Ms M
Kasagi and Ms Y Nakagawa for their technical assistance and
advice. This work was supported in part by the following grants
and foundations: CREST, Japan Science and Technology Agency;
Japan Society for the Promotion of Science Grant-in-Aid for
Scientific Research, grants 17109013, 17591411, 17591413,
18390367, 18590333, 18659384, 18790964, 19890336 and
19591509; The Ministry of Education, Culture, Sports, Science
and Technology Grant-in-Aid for Scientific Research on Priority
Areas, Grant 18015039; Third Term Comprehensive Ten-Year
Strategy for Cancer Control, Grant 16271201.
REFERENCES
Gorbsky GJ (2004) Mitosis: MCAK under the aura of Aurora B. Curr Biol
14: R346–R348
Helenius J, Brouhard G, Kalaidzidis Y, Diez S, Howard J (2006) The
depolymerizing kinesin MCAK uses lattice diffusion to rapidly target
microtubule ends. Nature 441: 115–119
Holmfeldt P, Stenmark S, Gullberg M (2004) Differential functional
interplay of TOGp/XMAP215 and the KinI kinesin MCAK during
interphase and mitosis. EMBO J 23: 627–637
Holmfeldt P, Zhang X, Stenmark S, Walczak CE, Gullberg M (2005)
CaMKIIgamma-mediated inactivation of the Kin I kinesin MCAK is
essential for bipolar spindle formation. EMBO J 24: 1256–1266
Honore S, Pasquier E, Braguer D (2005) Understanding microtubule
dynamics for improved cancer therapy. Cell Mol Life Sci 62: 3039–3056
Kline-Smith SL, Walczak CE (2002) The microtubule-destabilizing kinesin
XKCM1 regulates microtubule dynamic instability in cells. Mol Biol Cell
13: 2718–2731
Kono S (1996) Dietary factors for gastrointestinal cancers: a worldwide
overview. Gann Monogr Cancer Res 44: 29–39
Lawrence CJ, Dawe RK, Christie KR, Cleveland DW, Dawson SC, Endow SA,
Goldstein LS, Goodson HV, Hirokawa N, Howard J, Malmberg RL,
McIntosh JR, Miki H, Mitchison TJ, Okada Y, Reddy AS, Saxton WM,
Schliwa M, Scholey JM, Vale RD, Walczak CE, Wordeman L (2004) A
standardized kinesin nomenclature. J Cell Biol 167: 19–22
Mimori K, Mori M, Shiraishi T, Fujie T, Baba K, Haraguchi M, Abe R, Ueo H,
Akiyoshi T (1997) Clinical significance of tissue inhibitor of metallopro-
teinase expression in gastric carcinoma. Br J Cancer 76: 531–536
Mori M, Barnard GF, Staniunas RJ, Jessup JM, Steele Jr GD, Chen LB
(1993a) Prothymosin-alpha mRNA expression correlates with that of
c-myc in human colon cancer. Oncogene 8: 2821–2826
Mori M, Staniunas RJ, Barnard GF, Jessup Jr JM, Steele GD, Chen LB
(1993b) The significance of carbonic anhydrase expression in human
colorectal cancer. Gastroenterology 105: 820–826
Nakamura Y, Tanaka F, Haraguchi N, Mimori K, Matsumoto T, Inoue H,
Yanaga K, Mori M (2007) Clinicopathological and biological significance
of mitotic centromere-associated kinesin overexpression in human
gastric cancer. Br J Cancer 97: 543–549
Ogawa K, Utsunomiya T, Mimori K, Tanaka Y, Tanaka F, Inoue H,
Murayama S, Mori M (2004) Clinical significance of elongation
factor-1 delta mRNA expression in oesophageal carcinoma. Br J Cancer
91: 282–286
Parkin DM, Bray F, Ferlay J, Pisani P (2001) Estimating the world cancer
burden: Globocan 2000. Int J Cancer 94: 153–156
Japanese Society for Cancer Colon and Rectum (1998) General Rules for
Clinical and Pathological Studies on Cancer of the Colon, Rectum and
Anus 6th edn. Tokyo: Kanehara
Scanlan MJ, Welt S, Gordon CM, Chen YT, Gure AO, Stockert E, Jungbluth
AA, Ritter G, Jager D, Jager E, Knuth A, Old LJ (2002) Cancer-related
serological recognition of human colon cancer: identification of potential
diagnostic and immunotherapeutic targets. Cancer Res 62: 4041–4047
Schumacher P, Dineen S, Barnett Jr C, Fleming J, Anthony T (2007) The
metastatic lymph node ratio predicts survival in colon cancer. Am J Surg
194: 827–831; discussion 831–822
Shimo A, Tanikawa C, Nishidate T, Lin ML, Matsuda K, Park JH, Ueki T,
Ohta T, Hirata K, Fukuda M, Nakamura Y, Katagiri T (2008) Involvement
of kinesin family member 2C/mitotic centromere-associated kinesin
overexpression in mammary carcinogenesis. Cancer Sci 99: 62–70
Tomonaga T, Matsushita K, Ishibashi M, Nezu M, Shimada H, Ochiai T,
Yoda K, Nomura F (2005) Centromere protein H is up-regulated in
primary human colorectal cancer and its overexpression induces
aneuploidy. Cancer Res 65: 4683–4689
Tsukuma H, Ajiki W, Oshima A (2004) [Cancer incidence in Japan]. Gan To
Kagaku Ryoho 31: 840–846
Vale RD, Fletterick RJ (1997) The design plan of kinesin motors. Annu Rev
Cell Dev Biol 13: 745–777
Wittmann T, Hyman A, Desai A (2001) The spindle: a dynamic assembly of
microtubules and motors. Nat Cell Biol 3: E28–E34
Wordeman L, Mitchison TJ (1995) Identification and partial characteriza-
tion of mitotic centromere-associated kinesin, a kinesin-related protein
that associates with centromeres during mitosis. J Cell Biol 128: 95–104
Wordeman L, Wagenbach M, von Dassow G (2007) MCAK facilitates
chromosome movement by promoting kinetochore microtubule turn-
over. J Cell Biol 179: 869–879
MCAK is a novel prognostic marker for colorectal cancer
K Ishikawa et al
1829
British Journal of Cancer (2008) 98(11), 1824–1829 & 2008 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
s